• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Current COPD Cutoff Confirmed: JAMA Study Highlights

Slideshow

Confirmed: FEV1:FVC <0.70 proves to be the optimal threshold to identify risk of COPD vs less than LLN and other fixed values.

The ratio of the forced expiratory volume in the first second to the forced vital capacity (FEV1/FVC) is measured relatively easily in the clinic using spirometry. Many professional organizations (eg, American College of Physicians, American College of Chest Physicians, European Respiratory Society) have long recommended the ratio of FEV1/FVC

Related Content
Decrease in BMI Linked to Increased Risk for Severe Exacerbations, All-Cause Mortality in COPD / image credit weight loss/gain: ©missbobbit/stock.adobe.com

Decrease in BMI Linked to Increased Risk for Severe Exacerbations, All-Cause Mortality in COPD

April 19th 2024
Article

Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.

Tezepelumab for COPD Moves into Phase 3 Planning, Says Amgen / image credit Amgen logo ©MichaelVi/stock.adobe.com

Tezepelumab for COPD Moves into Phase 3 Planning

April 17th 2024
Article

Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.

AstraZeneca launches THARROS phase 3 trial / image credit ©Sundry Photography/stock.adobe.com

AstraZeneca Launches Phase 3 THARROS Trial of Breztri to Reduce Cardiopulmonary Events in COPD

March 14th 2024
Article

THARROS is the first phase 3 RCT to evaluate an inhaled triple combination therapy for reduction of adverse cardiopulmonary events in people with COPD, says AstraZeneca.

Boehringer Ingelheim Will Cap Out of Pocket Costs for Inhalers at $35 per Month / image credit inhalers ©beltado/stock.adobe.com

Boehringer Ingelheim Will Cap Out of Pocket Costs for Inhalers at $35 per Month

March 7th 2024
Article

The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.

Impact of Regular Exercise on Hospitalization in Patients with COPD: Daily Dose / image credit: ©New Africa/AdobeStock

Impact of Regular Exercise on Hospitalization in Patients with COPD: Daily Dose

February 26th 2024
Article

Your daily dose of the clinical news you may have missed.

FDA Accepts Dupilumab sBLA for Priority Review for Treatment of COPD with Type 2 Inflammation / image credit FDA logo courtesy of US FDA

FDA Accepts Dupilumab sBLA for Priority Review for Treatment of COPD with Type 2 Inflammation

February 23rd 2024
Article

A PDUFA date of June 27, 2024 has been set for approval of a 6th dupilimab indication - as add-on therapy for individuals with COPD and eosinophilic inflammation.

© 2024 MJH Life Sciences

All rights reserved.